An ultralong-acting tenofovir ProTide nanoformulation achieves monthslong HBV suppression

Treatment of chronic hepatitis B virus (HBV) requires lifelong daily therapy. However, suboptimal adherence to the existing daily therapy has led to the need for ultralong-acting antivirals. A lipophilic and hydrophobic ProTide was made by replacing the alanyl isopropyl ester present in tenofovir al...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Srijanee, Wang, Weimin, Ganesan, Murali, Fonseca-Lanza, Franchesca, Cobb, Denise A., Bybee, Grace, Sun, Yimin, Guo, Lili, Hanson, Brandon, Cohen, Samuel M., Gendelman, Howard E., Osna, Natalia A., Edagwa, Benson J., Poluektova, Larisa Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788773/
https://www.ncbi.nlm.nih.gov/pubmed/36563152
http://dx.doi.org/10.1126/sciadv.ade9582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788773/
https://www.ncbi.nlm.nih.gov/pubmed/36563152
http://dx.doi.org/10.1126/sciadv.ade9582

Ejemplares similares